Dr. Jonathan Aschoff
Dr. Jonathan Aschoff is a managing director at Opus National Capital Markets. Prior to joining the firm in 2016, he held positions as a senior biotechnology analyst at Brean Murray, Carret & Co. and Friedman Billings Ramsey & Co. Inc., as a senior analyst at what is now RBC Inc. and also served as an analyst at Sturza Institutional Research. Prior to his work on Wall Street, Dr. Aschoff was a research technician at New England Medical Center. It was at Tufts University that Dr. Aschoff earned his Ph.D. in molecular biology and microbiolog,y as well as his bachelor's degree in biology.
Recent Articles about Biofrontera Inc.
Mass. Biotech Receives FDA Approval 10/07/2024
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note.
Biotech Co.'s Target Price Significantly Higher Than Current 03/19/2024
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Approved Drug for Skin Condition Shown Safe at Higher Dose 09/01/2023
Based on these positive Phase 1 trial results in actinic keratosis, the biopharma developer will seek label expansion in the U.S., noted a ROTH Capital Partners report.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
